Differential immune regulation of activated T cells between cutaneous and mucosal leishmaniasis as a model for pathogenesis

Parasite Immunology

Volumn 29, Issue 5, 2007, Pages 251-258

  Carvalho, L P ^a   Passos, S ^a   Bacellar, O ^a   Lessa, M ^a   Almeida, R P ^a   Magalhaes A ^a   Dutra, W O ^b   Gollob, K J ^b   Machado, P ^a   Ribeiro De Jesus, A ^a  

^a FEDERAL UNIVERSITY OF BAHIA   (Brazil)

^b FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

Activated T cells; Cutaneous leishmaniasis; Cytokines; Human leishmaniasis; Mucosal leishmaniasis

Indexed keywords

BIOCHEMICAL MARKER; CD28 ANTIGEN; CD69 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 2; L SELECTIN; MEGLUMINE ANTIMONATE; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY;

APOPTOSIS; ARTICLE; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; HUMAN; HUMAN CELL; IMMUNOREGULATION; IMMUNOSTIMULATION; LEISHMANIASIS; MUCOSA LEISHMANIASIS; PATHOGENESIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKIN LEISHMANIASIS; T LYMPHOCYTE ACTIVATION;

ADOLESCENT; ADULT; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION; CHILD; FEMALE; HUMANS; INTERFERON TYPE II; INTERLEUKIN-12; INTERLEUKIN-15; INTERLEUKIN-2; LEISHMANIASIS, CUTANEOUS; LEISHMANIASIS, MUCOCUTANEOUS; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; T-LYMPHOCYTES;

EID: 34247137487     PISSN: 01419838     EISSN: 13653024     Source Type: Journal    
DOI: 10.1111/j.1365-3024.2007.00940.x     Document Type: Article

References (32)

1. Jones TC, Johnson WD Jr, Barretto AC et al. Epidemiology of American cutaneous leishmaniasis due to Leishmania braziliensis braziliensis. J Infect Dis 1987; 156: 73-83.
2. Carvalho EM, Badaro R, Reed SG, Jones TC & Johnson WD Jr. Absence of gamma interferon and interleukin 2 production during active visceral leishmaniasis. J Clin Invest 1985; 76: 2066-2069.
3. Convit J, Castellanos PL, Ulrich M et al. Immunotherapy of localized, intermediate, and diffuse forms of American cutaneous leishmaniasis. J Infect Dis 1989; 160: 104-115.
4. Bacellar O, Lessa H, Schriefer A et al. Up-regulation of Th1-type responses in mucosal leishmaniasis patients. Infect Immun 2002; 70: 6734-6740.
5. Scott P, Natovitz P, Coffman RL, Pearce E & Sher A. Immunoregulation of cutaneous leishmaniasis. T cell lines that transfer protective immunity or exacerbation belong to different T helper subsets and respond to distinct parasite antigens. J Exp Med 1988; 168: 1675-1684.
6. Scott P, Pearce E, Cheever AW, Coffman RL & Sher A. Role of cytokines and CD4+ T-cell subsets in the regulation of parasite immunity and disease. Immunol Rev 1989; 112: 161-182.
7. Pirmez C, Yamamura M, Uyemura K, Paes-Oliveira M, Conceicao-Silva F & Modlin RL. Cytokine patterns in the pathogenesis of human leishmaniasis. J Clin Invest 1993; 91: 1390-1395.
8. Bittencourt AL & Barral A. Evaluation of the histopathological classifications of American cutaneous and mucocutaneous leishmaniasis. Mem Inst Oswaldo Cruz 1991; 86: 51-56.
9. Machado P, Kanitakis J, Almeida R, Chalon A, Araujo C & Carvalho EM. Evidence of in situ cytotoxicity in American cutaneous leishmaniasis. Eur J Dermatol 2002; 12: 449-451.
10. Antonelli LR, Dutra WO, Almeida RP, Bacellar O, Carvalho EM & Gollob KJ. Activated inflammatory T cells correlate with lesion size in human cutaneous leishmaniasis. Immunol Lett 2005; 101: 226-230.
11. Almeida R, D'Oliveira A Jr, Machado P et al. Randomized, double-blind study of stibogluconate plus human granulocyte macrophage colony-stimulating factor versus stibogluconate alone in the treatment of cutaneous Leishmaniasis. J Infect Dis 1999; 180: 1735-1737.
12. Lessa HA, Machado P, Lima F et al. Successful treatment of refractory mucosal leishmaniasis with pentoxifylline plus antimony. Am J Trop Med Hyg 2001; 65: 87-89.
13. Faria DR, Gollob KJ, Barbosa J Jr et al. Decreased in situ expression of interleukin-10 receptor is correlated with the exacerbated inflammatory and cytotoxic responses observed in mucosal leishmaniasis. Infect Immun 2005; 73: 7853-7859.
14. Da-Cruz AM, de Oliveira MP, De Luca PM, Mendonca SC & Coutinho SG. Tumor necrosis factor-alpha in human American tegumentary leishmaniasis. Mem Inst Oswaldo Cruz 1996; 91: 225-229.
15. Carvalho EM, Johnson WD, Barreto E et al. Cell mediated immunity in American cutaneous and mucosal leishmaniasis. J Immunol 1985; 135: 4144-4148.
16. Antonelli LR, Dutra WO, Almeida RP, Bacellar O & Gollob KJ. Antigen specific correlations of cellular immune responses in human leishmaniasis suggests mechanisms for immunoregulation. Clin Exp Immunol 2004; 136: 341-348.
17. Bottrel RL, Dutra WO, Martins FA et al. Flow cytometric determination of cellular sources and frequencies of key cytokine-producing lymphocytes directed against recombinant LACK and soluble Leishmania antigen in human cutaneous leishmaniasis. Infect Immun 2001; 69: 3232-3239.
18. Rocha PN, Almeida RP, Bacellar O et al. Down-regulation of Th1 type of response in early human American cutaneous leishmaniasis. J Infect Dis 1999; 180: 1731-1734.
19. Louzir H. Immunologic determinants of disease evolution in localized cutaneous leishmaniasis due to leishmania major. J Inf Dis 1998; 177: 1687-1695.
20. Melby PC, Andrade-Narvaez FJ, Darnell BJ, Valencia-Pacheco G, Tryon VV & Palomo-Cetina A. Increased expression of proin-flammatory cytokines in chronic lesions of human cutaneous leishmaniasis. Infect Immun 1994; 62: 837-842.
21. Melby PC, Andrade-Narvaez F, Darnell BJ & Valencia-Pacheco G. In situ expression of interleukin-10 and interleukin-12 in active human cutaneous leishmaniasis. FEMS Immunol Med Microbiol 1996; 15: 101-107.
22. Murphy ML, Cotterell SE, Gorak PM, Engwerda CR & Kaye PM. Blockade of CTLA-4 enhances host resistance to the intracellular pathogen, Leishmania donovani. J Immunol 1998; 161: 4153-4160.
23. Murray HW, Lu CM, Brooks EB, Fichtl RE, DeVecchio JL & Heinzel FP. Modulation of T-cell costimulation as immunotherapy or immunochemotherapy in experimental visceral leishmaniasis. Infect Immun 2003; 71: 6453-6462.
24. Stuyt RJ, Kim SH, Reznikov LL et al. Regulation of Staphylococcus epidermidis-induced IFN-gamma in whole human blood: the role of endogenous IL-18, IL-12, IL-1, and TNF. Cytokine 2003; 21: 65-73.
25. Bacellar O, Brodskyn C, Guerreiro J et al. Interleukin-12 restores interferon-gamma production and cytotoxic responses in visceral leishmaniasis. J Infect Dis 1996; 173: 1515-1518.
26. Lazarevic V, Yankura DJ, DiVito SJ & Flynn JL. Induction of mycobacterium tuberculosis-specific primary and secondary T-cell responses in interleukin-15-deficient mice. Infect Immun 2005; 73: 2910-2922.
27. Scott P & Scharton T. Interaction between the innate and the acquired immune system following infection of different mouse strains with Leishmania major. Ann N Y Acad Sci 1994; 730: 84-92.
28. Hasan MS, Kallas EG, Thomas EK, Looney J, Campbell M & Evans TG. Effects of interleukin-15 on in vitro human T cell proliferation and activation. J Interferon Cytokine Res 2000; 20: 119-123.
29. Azimi N, Jacobson S, Leist T & Waldmann TA. Involvement of IL-15 in the pathogenesis of human T lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis: implications for therapy with a monoclonal antibody directed to the IL-2/15R beta receptor. J Immunol 1999; 163: 4064-4072.
30. Zhang X, Sun S, Hwang I, Tough DF & Sprent J. Potent and selective stimulation of memory-phenotype CD8+ T cells in vivo by IL-15. Immunity 1998; 8: 591-599.
31. Santos SB, Porto AF, Muniz AL et al. Exacerbated inflammatory cellular immune response characteristics of HAM/TSP is observed in a large proportion of HTLV-I asymptomatic carriers. BMC Infect Dis 2004; 4: 7.
32. Sestak K, Merritt CK, Borda J et al. Infectious agent and immune response characteristics of chronic enterocolitis in captive rhesus macaques. Infect Immun 2003; 71: 4079-4086.